Cargando…
In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection
COVID-19 has currently become the biggest challenge in the world. There is still no specific medicine for COVID-19, which leaves a critical gap for the identification of new drug candidates for the disease. Recent studies have reported that the small-molecule enoxacin exerts an antiviral activity by...
Autores principales: | Ahmadi, Amirhossein, Moradi, Sharif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119475/ https://www.ncbi.nlm.nih.gov/pubmed/33986351 http://dx.doi.org/10.1038/s41598-021-89605-6 |
Ejemplares similares
-
Rational Identification of Enoxacin as a Novel V-ATPase-Directed Osteoclast Inhibitor
por: Toro, Edgardo J, et al.
Publicado: (2012) -
Enoxacin and bis-enoxacin stimulate 4T1 murine breast cancer cells to release extracellular vesicles that inhibit osteoclastogenesis
por: Vracar, Taylor C., et al.
Publicado: (2018) -
RNAi suppressor: The hidden weapon of SARS-CoV
por: Karjee, Sumona, et al.
Publicado: (2020) -
The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives
por: Jałbrzykowska, Karolina, et al.
Publicado: (2022) -
Proteomics Analysis Reveals Bacterial Antibiotics Resistance Mechanism Mediated by ahslyA Against Enoxacin in Aeromonas hydrophila
por: Li, Zhen, et al.
Publicado: (2021)